EIF2AK3 and hepatocellular carcinoma: Caraglia et al. demonstrated that both the oxidative stress status and pERK activity in peripheral blood mononuclear cells have optimal value in predicting response to sorafenib plus octreotide treatment in advanced HCC patients (25).